BAY 94-9027 provides effective long-term prophylaxis in pediatric patients: Interim results of the PROTECT VIII Kids extension study

被引：0
|
作者：
Kenet, Gili [1 ]
Biss, Tina [2 ]
Steele, MacGregor [3 ]
Linardi, Camila [4 ]
Tseneklidou-Stoeter, Despina [5 ]
Saxena, Kapil [4 ]
机构：
[1] Chaim Sheba Med Ctr, Israel Natl Hemophilia Ctr, Tel Hashomer, Israel
[2] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England
[3] Univ Calgary, Alberta Childrens Hosp, Cumming Sch Med, Calgary, AB, Canada
[4] Bayer, Whippany, NJ USA
[5] Bayer, Berlin, Germany
来源：
HAEMOPHILIA | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
M-FPMED02-
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [21] SAFETY AND EFFICACY OF BAY 94-9027 PROPHYLAXIS IN PATIENTS WITH SEVERE HAEMOPHILIA A: INTERIM RESULTS OF A POST-MARKETING INTERVENTIONAL STUDY
    Holme, P. A.
    Poulsen, L. H.
    Enriquez, M. Maas
    Tueckmantel, C.
    Alvarez Roman, M. T.
    De Cristofaro, R.
    [J]. HAEMOPHILIA, 2021, 27 : 125 - 126
  • [22] Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII)
    Jane R. Wells
    Adam Gater
    Chris Marshall
    Theo Tritton
    Parth Vashi
    Sophia Kessabi
    [J]. The Patient - Patient-Centered Outcomes Research, 2019, 12 : 611 - 619
  • [23] PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
    Santagostino, Elena
    Kenet, Gili
    Fischer, Kathelijn
    Biss, Tina
    Ahuja, Sanjay
    Steele, MacGregor
    [J]. HAEMOPHILIA, 2020, 26 (03) : E55 - E65
  • [24] Protect VIII: Effective Protection With BAY 94-9027 Prophylaxis Given Twice Weekly, Every 5 Days, Or Every 7 Days
    Negrier, C.
    Chambost, H.
    Poulsen, L. H.
    Enriquez, M. Maas
    Lalezari, S.
    Pabinger, I.
    Wang, M.
    [J]. HAEMOPHILIA, 2017, 23 : 100 - 101
  • [25] Extended Interval Prophylaxis with Bay 94-9027 for > 4 Years Leads to Median Spontaneous Annualized Bleeding Rates < 1 in the Protect VIII Extension
    Simpson, Mindy
    Ahuja, Sanjay
    Tseneklidou-Stoeter, Despina
    Lalezari, Shadan
    [J]. BLOOD, 2018, 132
  • [26] Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII)
    Wells, Jane R.
    Gater, Adam
    Marshall, Chris
    Tritton, Theo
    Vashi, Parth
    Kessabi, Sophia
    [J]. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2019, 12 (06): : 611 - 619
  • [27] Bleeding Phenotype with Various Bay 94-9027 Dosing Regimens: Subanalyses from the Protect VIII Study
    Boggio, Lisa N.
    Hong, Walter
    Wang, Maria
    Eyster, M. Elaine
    Michaels, Lisa A.
    [J]. BLOOD, 2014, 124 (21)
  • [28] Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension
    Reding, Mark T.
    Lalezari, Shadan
    Pabinger, Ingrid
    Enriquez, Monica Maas
    Ducore, Jonathan M.
    [J]. BLOOD, 2018, 132
  • [29] Improved Bleeding Outcomes in Patients Who Switched From Sucrose-Formulated rFVIII to BAY 94-9027 Prophylaxis in PROTECT VIII
    Reding, Mark
    Moulton, Thomas
    Rak, Erika Soltes
    Simpson, Mindy L.
    [J]. BLOOD, 2020, 136
  • [30] BAY 94-9027 PROPHYLAXIS SUSTAINS FACTOR VIII TROUGH LEVELS ABOVE 1% IN ALL TREATMENT REGIMENS IN PATIENTS WITH SEVERE HAEMOPHILIA A FROM PROTECT VIII
    Reding, M. T.
    Mancuso, M. E.
    Poulsen, L. H.
    Enriquez, M. Maas
    Tueckmantel, C.
    Solms, A.
    Holme, P. A.
    [J]. HAEMOPHILIA, 2021, 27 : 47 - 47
12345